Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES Trial

NCT06470971 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Advanced Malignant Solid Neoplasm
Hematopoietic and Lymphatic System Neoplasm

Interventions

BIOLOGICAL: Anti-PD-L1 Monoclonal Antibody
BIOLOGICAL: Anti-PD1 Monoclonal Antibody
PROCEDURE: Biopsy
PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Scan
PROCEDURE: Computed Tomography
PROCEDURE: Magnetic Resonance Imaging
OTHER: Quality-of-Life Assessment
BIOLOGICAL: Siltuximab

Sponsor

Yuanquan Yang